A Pre-Clinical Safety Evaluation of SBP (HBsAg-Binding Protein) Adjuvant for Hepatitis B Vaccine

PLoS One

Rui Liu¹  Baoxiu Liu¹  Inam Ullah Khan¹  Jun Xie¹  Jingbo Wang¹  Naishuo Zhu¹  Caixia Su¹ 

[1] Laboratory of Molecular Immunology, State Key Laboratory of Genetic Engineering, Institute of Biomedical Science, School of Life Sciences, Fudan University, Shanghai, China

关键词: Vaccines;    Immunologic adjuvants;    Antibodies;    Enzyme-linked immunoassays;    Antibody production;    Guinea pigs;    Hepatitis B;    Hepatitis B virus;   

DOI  :  10.1371/journal.pone.0170313

学科分类：医学（综合）

来源: Public Library of Science

【 摘 要 】

Although adjuvants are a common component of many vaccines, there are few adjuvants licensed for use in humans due to concerns about their toxic effects. There is a need to develop new and safe adjuvants, because some existing vaccines have low immunogenicity among certain patient groups. In this study, SBP, a hepatitis B surface antigen binding protein that was discovered through screening a human liver cDNA expression library, was introduced into hepatitis B vaccine. A good laboratory practice, non-clinical safety evaluation was performed to identify the side effects of both SBP and SBP-adjuvanted hepatitis B vaccine. The results indicate that SBP could enhance the HBsAg-specific immune response, thus increasing the protection provided by the hepatitis B vaccine. The safety data obtained here warrant further investigation of SBP as a vaccine adjuvant.

【 授权许可】

CC BY